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Background: Postoperative pain is one of the most common complications. The aim of this study is to evaluate 
the analgesic efficacies of dexketoprofen trometamol and two different dosages of dexketoprofen trometamol + 
thiocolchicoside combination in the impacted third molar tooth operation.
Material and Methods: This randomized, double-blind study included 75 patients who did not have any disease. 
Patients were assigned to 3 groups. Group 1 received 25 mg dexketoprofen trometamol + 4 mg thiocholchicoside, 
Group 2 received 25 mg dexketoprofen trometamol +8 mg thiocholchicoside, and Group 3 received 25 mg dexke-
toprofen trometamol. In each group, the analgesic medication was administered twice a day, starting 1 hour before 
the operation. The level of pain was assessed with VAS.
Results: Patient age varied from 18 to 36 years. Of all patients, 59.2% (n=42) were female and 40.8% (n=29) were 
male. Drug side effects were observed in 28.17% (n=20) of the patients. Mean 24th hour VAS score was lower in 
dexketoprofen trometamol + 8 mg thiocolchicoside group compared to dexketoprofen trometamol group (p<0.05). 
There was no statistically significant difference between the three groups regarding drug side effects (p>0.05). 
Conclusions: Dexketoprofen trometamol + 8 mg thiocolchicoside combination has higher analgesic efficacy com-
pared to dexketoprofen trometamol. More studies are needed to interpret the analgesic and anti-inflammatory 
effects of thiocholchicoside + dexketoprofen trometamol combination.
 
Key words: Analgesic, dexketoprofen trometamol, thiocolchicoside, third molar surgery.
doi:10.4317/medoral.22590
http://dx.doi.org/doi:10.4317/medoral.22590
Cigerim L, Kaplan V. Evaluation of the analgesic efficacies of Dexketo-
profen Trometamol and Dexketoprofen Trometamol + Thiocolchicoside 
combinations in the impacted third molar surgery: Randomised clinical 
trial. Med Oral Patol Oral Cir Bucal. 2019 Jan 1;24 (1):e114-22.   
http://www.medicinaoral.com/medoralfree01/v24i1/medoralv24i1p114.pdf
Article Number: 22590          http://www.medicinaoral.com/
© Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946
eMail:  medicina@medicinaoral.com 
Indexed in: 
Science Citation Index Expanded
Journal Citation Reports
Index Medicus, MEDLINE, PubMed
Scopus, Embase and Emcare 
Indice Médico Español
Med Oral Patol Oral Cir Bucal. 2019 Jan 1;24 (1):e114-22.                                   Efficacies of Dexketoprofen Trometamol and Dexketoprofen Trometamol + Thiocolchicoside combinations
e115
Introduction
Lower third molars are the most commonly impacted 
teeth in jaws (1). Surgical extraction of these teeth is one 
of the most commonly performed procedures in Oral 
and Maxillofacial Surgery clinic (2). Most common 
complications observed after extraction of impacted 
lower third molar include pain, swelling and trismus 
(3,4). These complications have negative effect on pa-
tient’s return to daily life at the postoperative period and 
can reduce life quality (5).
Following extraction of impacted lower third molar, 
the pain starts once the effect of local anesthetic sub-
sides, and is usually worst within the first 24 hours (6). 
Various methods have been investigated for prevention 
and/or treatment of postoperative pain. These include 
medications such as analgesics, steroids, muscle relax-
ants, antibiotics, as well as methods such as mouthwash 
use, cold application, low-dose laser therapy, different 
flap techniques, different closing techniques, drainage, 
and prp-prf application (7-18). Among these methods, 
non-steroid anti-inflammatory drugs (NSAID’s) with 
anti-inflammatory and analgesic effects have been most 
extensively studied. NSAIDs can be used alone or in 
combination with paracetamol or opioid analgesics 
(19,20).
NSAIDs act by inhibiting COX (cyclooxygenase) path-
way and prostaglandin synthesis. In addition to the di-
rect effect, inhibition of prostaglandin synthesis also 
causes an indirect effect by acting on other inflamma-
tory mediators such as kinins (21).
Dexketoprofen trometamol is a propionic acid group of 
NSAID, and is S (+) enantiomer of ketoprofen. It is a 
COX-1 and COX-2 inhibitor with well-known anti-in-
flammatory and analgesic effects. Dexketoprofen tro-
metamol reaches a plasma peak concentration approxi-
mately 30 minutes after its oral administration. It has 
high affinity to plasma proteins (99%) (22).
Thiocholcicoside is a muscle relaxant derived semi-syn-
thetically from the cholchicoside, a natural glycoside. 
It shows selective agonist action by binding gamma-
aminobutyric acid (GABA) receptors and glycinergic 
receptors. The myorelaxant effect occurs as a results of 
direct activation of GABA receptors at the spinal level. 
It also has analgesic and anti-inflammatory effect. The 
plasma peak concentration is reached approximately 1 
hour after oral administration (23).
Studies evaluating the efficacies of NSAID’s in preven-
tion or reduction of pain afer extraction of impacted 
lower third molar did not yield a consensus on the most 
effective and safe optimum analgesic, so that there is 
still research going on this subject. The effervescent 
tablet form of dexketoprofen trometamol + thiocolchi-
coside combination is a new drug, and its effect has not 
been studied. The aim of this study is to evaluate the 
analgesic efficacies of dexketoprofen trometamol (25 
mg dexketoprofen trometamol) and two different dos-
ages of dexketoprofen trometamol + thiocolchicoside 
combination (25 mg dexketoprofen trometamol + 4 mg 
thiocolchicoside and 25 mg dexketoprofen trometamol 
+ 8 mg thiocolchicoside) administered 1 hour before ex-
traction of impacted lower third molar.
Material and Methods
This study was conducted with individuals who came 
with the indication of extraction of impacted lower third 
molar upon presenting to Van Yuzuncu Yil University, 
Faculty of Dentistry, Department of Oral and Maxil-
lofacial Surgery. The inclusion criteria of this random-
ized double-blinded study were absence of any systemic 
disease (Class 1 individuals according to American So-
ciety of Anesthesiology), absence of smoking/alcohol 
consumption, absence of allergy to any of the drugs 
used in the study, absence of pregnancy/lactating state, 
no history of any medication use during at least 1 week 
before the operation. Individuals who did not respond 
despite several telephone calls after the surgery, those 
who developed alveolitis and received additional treat-
ment for this reason, those who did not show up controls 
on postoperative days 2 and 7, those who did not fill 
VAS (visual analogue scale) or filled it incompletely, or 
those whose operation took more than 30 minutes were 
excluded from the study.
Presence of impacted lower third molar was confirmed 
in individuals presenting to the clinic by clinical and 
radiographic examination. Impacted lower third molar 
that were Class 1 (Class A or B) or Class 2 according 
to Pell and Gregory Classification, vertical or mesioan-
gular according to Winter Classiffication, and showed 
partial or compete bone retention were selected for the 
study. The individuals were informed about the study, 
and those who volunteered signed a consent form. The 
study was approved by Van Yuzuncu Yil University 
Clinical Research Ethics Committee, and all surgical 
procedures were carried out in accordance with the Hel-
sinki Declaration. 
A total of 75 patients were enrolled in the study. Each 
patient had one impacted lower third molar with indi-
cation of extraction. The medication given to patients 
were encoded with the numbers 1, 2, 3 by the assistant 
personnel, and were bottled in different vials. Ran-
domization of medicines was achieved using an online 
software (http://graphpad.com/quickcalcs/randomize1.
cfm). One hour before the operation, the assistant per-
sonnel recorded the code of the medicines on the patient 
file that was enclosed in an envelope, and the envelopes 
were opened by the same personnel only.
Anesthesia of inferior alveolar nerve, lingual nerve and 
buccal nerve was achieved using 2 ml ampoules con-
taining 40 mg/ml articaine hydrochloride + 0.01 mg/
ml epinephrine (Maxicaine Fort, Vem Pharmaceutical 
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Industry and Trade Co. Ltd, Istanbul, Turkey). 1.2 ml 
of the solution was deposited for inferior alveolar nerve 
+ lingual nerve, and 0.5 ml of the solution was depos-
ited for buccal nerve. All surgical procedures were per-
formed by the same surgeon following the same surgical 
procedure. Following elevation of a three-cornered flap, 
the bone was elevated under physiological cooling with 
sterile saline, and the teeth were removed with incisions 
when necessary. The extraction socket was irrigated 
with sterile saline, and the incision line was closed pri-
marily with 3/0 silk suture. During the postoperative 5 
days, patients in Group 1 received 25 mg dexketoprofen 
trometamol + 4 mg thiocolchicoside effervescent tab-
let (Dexplus 25/4, Vitalis Pharmaceuticals Industry and 
Trade Co. Ltd. Istanbul, Turkey) twice daily; patients in 
Group 2 received 25 mg dexketoprofen trometamol + 8 
mg thiocholchicoside effervescent tablet (Dexplus 25/8, 
Vitalis Pharmaceuticals Industry and Trade Co. Ltd. 
Istanbul, Turkey) twice daily; and patients in Group 
3 received 25 mg dexketoprofen trometamol tablets 
(Arveles, Ufsa Pharmaceutical Industry and Trade Co. 
Ltd. Istanbul) twice daily. The patients were advised to 
use paracetamol (Parol 500 mg tablet, Atabay Pharma-
ceuticals, Istanbul) only when they needed additional 
analgesic. In addition to the study medication, mouth-
wash containing 0.06% chlorhexidine glucanate (Mira-
fluor chx 100 ml, Hager & Werken GmbH & Co, KG, 
Duisburg, Germany) was prescribed three times a day. 
Patients were recommended not to drive a vehicle, etc.
Post-operative controls and measurements were per-
formed by another surgeon who was blinded to treat-
ment allocations. The measurements and other informa-
tion were recorded in the patient file by the assistant 
personnel. Wound healing was assessed by evaluation 
of factors such as wound gap and its size, dry socket, 
and pus drainage. Drug side effects were questioned at 
the postoperative controls, and was recorded to patient’s 
file when present.
Postoperative pain was assessed with VAS at 1st, 2nd, 
3rd, 6th, 8th and 24th postoperative hours and 2nd, 3rd 
and 5th days. 
-Statistical Analysis
Data were analyzed with SPSS statistical software (IBM 
Statistics (21.0). For evaluating study data, in addition to 
calculating descriptive statistics (mean, standard devia-
tion, median, frequency, proportion, minimum, maxi-
mum), comparison of quantitative data between three 
or more groups was made with one-way ANOVA test 
for normally distributed data, or Kruskal Wallis test for 
non-normally distributed data. Mann-Whitney U tests 
were used in cases which within group differences were 
detected with Kruskal Wallis test, and p<0.05 was ac-
cepted as statistically significant.
Sample size was estimated using data from Eroglu and 
colleagues (24). It was considered necessary to include 
20 patients per group to be able to detect a 50% differ-
ence in pain levels (type I error frequency: 0.05, power: 
0.80). We included 25 patients per group considering 
losses to the follow up.
Results
Of 75 patients operated, 4 developed alveolitis and these 
patients were excluded from the study. Of 71 patients 
included in the analysis, 59.2% (n=42) were female and 
40.8% (n=33) were male. Patients’ age varied from 18 to 
36 years, with a mean age of 23.5±3.8 years. Drug side 
effects were observed in 28.17% (n=20) of the patients. 
Among patients developing drug side effects, 9.86% 
(n=7) had stomach complaint, 5.63% (n=4) had head-
ache/dizziness, 1.41% (n=1) had earache, 1.41%  (n=1) 
had stomach complaint + headache/dizziness + palpi-
tation +  chills, 9.86% (n=7) had stomach complaint + 
headache/dizziness (Table 1).
Patients’ age and gender distributions and side effect 
rates did not show statistically significant differences 
according to drug groups (p>0.05) (Table 2).
Patients’ mean VAS scores at 1st, 2nd, 3rd, 6th and 8th 
hours and 2nd, 3rd and 5th days did not show statistically 
significant differences according to drug groups, how-
ever, mean VAS scores of patients in dexketoprofen tro-
metamol + 8 mg thiocolchicoside were lower than mean 
VAS scores of patients in dexketoprofen group at all 
times (p>0.05). Mean 24th hour VAS scores of patients 
in dexketoprofen trometamol group was significantly 
higher compared to that of patients in dexketoprofen 
trometamol + 8 mg thiocolchicoside (p<0.05). The dif-
ference in 24th hour VAS scores between dexketoprofen 
trometamol + 4 mg thiocolchicoside and dexketoprofen 
trometamol + 8 mg thiocolchicoside groups, or between 
dexketoprofen trometamol + 4 mg thiocolchicoside and 
dexketoprofen trometamol groups was not statistically 
significant (p>0.05) (Table 3, Fig. 1). 
Highest mean VAS scores was observed at the 8th hour 
in all 3 drug groups. Mean VAS scores in dexketopro-
fen trometamol and dexketoprofen trometamol + 4 mg 
thiocolchicoside groups started to fall on the 3rd day, 
whereas in dexketoprofen trometamol + 8 mg thiocol-
chicoside group, they started to fall at the 24th hour.
Comparing of mean VAS scores among female patients, 
no significant differences were observed according to 
drug groups (p>0.05) (Table 4, Fig. 2). Comparing of 
mean VAS scores among male patients, no significant 
differences were observed according to drug groups 
(p>0.05) (Table 4, Fig. 3).
Discussion
One of the most common complications observed after 
extraction of impacted lower third molar is pain. There 
are many studies related to management and treatment 
of pain (25). Since NSAID’s create analgesia due to their 
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Min-Max (Median) Mean±Std. dev.
Age (year) 17 – 36 (23) 23.5±3.8
N %
Gender Female 42 59.2
Male 29 40.8
Side Effect No 51 71.83
Yes 20 28.17
Stomach complaint 7 9.86
Headache/Dizziness 4 5.63
Earache
Stomach complaint + Headache/Dizziness + Palpitation 
+ Chills











Trometamol + 4mg 
Thiocolchicoside
Dexketoprofen 





17 – 34 (22) 18 – 30 (24) 17 – 36 (23) F:0.905
Mean±Std. dev 22.68±3.93 23.87±3.22 24.04±4.29 a0.409
N (%) N (%) N (%)
Gender Female 15 (60) 14 (60.9) 13(56.5) χ2:0.101
Male 10 (40) 9 (39.1) 10 (43.5) b0.951
Side Effect No 17 (68) 17 (73.9) 17 (73.9) χ2:0,280
Yes 8 (32) 6 (26.1) 6 (26.1) b0,869
Table 2. Evaluation of age, gender and side effects according to drug groups.
aOneway Anova Test  bPearson Chi-Square Test
anti-inflammatory effects, and they have relatively less 
side effecs, they have been frequently used and investi-
gated in studies related with pain, and they are effective 
in mild to moderate pain. Paracetamol is a central act-
ing analgesic with little anti-inflammatory effect, and it 
is effective in mild pain. As it is a safe drug with little 
anti-inflammatory effect, it has often been used studies 
for rescue analgesia (7). Although steroids have greater 
anti-inflammatory effects compared to NSAID’s, they 
are not desired for long-term use due to their dose-de-
pendent side effects (8). Opiods have no anti-inflamma-
tory effect, the analgesic effect occurs through central 
action. They have limited use due to their potential for 
addiction (19). These reasons explain why NSAID’s are 
preferred in studies on impacted third molar; however, 
NSAID’s may fail to control severe pain within the first 
24 hours, particularly starting after the 6th postopera-
tive hour. It is thought that combination of NSAID’s 
with different ancillary analgesics without increasing 
its dose can create synergistic analgesic effect, and thus 
potential side effects can be reduced to minimum while 
controlling severe pain (20).
In the literature, the analgesic efficacy of dexketopro-
fen trometamol in extraction of impacted lower third 
molar has been evaluated in many studies. Bagan and 
colleagues found dexketoprofen trometamol in 12.5 
mg and 25 mg dosages were more effective than 575 
mg dipyrone (26). Jackson and colleagues found that 
analgesic efficacy of 25 mg dexketoprofen trometamol 
was similar to 50 mg refocoxib, and superior to placebo 
(27). In the study by Çağıran and colleagues preopera-
tive intravenous 50 mg dexketoprofen trometamol was 
found to be more effective than placebo (28). Eroglu 
and colleagues reported that 12.5 mg dexketoprofen 
trometamol had similar analgesic effect with 500 mg 
paracetamol (24). 
In studies using dexketoprofen trometamol in extrac-
tion of impacted lower third molar, the pain was at 





Trometamol + 4mg 
Thiocolchicoside
Dexketoprofen 
Trometamol + 8mg 
Thiocolchicoside
p
1st hour Min-Max (Median) 0-4 (0) 0-5 (0) 0-7 (0) χ2:4.22
Mean±Std. dev. 0.8±1.3 0.4±1.1 0.4±2.1 0.121
2nd hour Min-Max (Median) 0-8 (1) 0-5 (1) 0-6 (1) χ2:0.187
Mean±Std. dev. 1.5±2 1.4±1.7 1.6±1.9 0.911
3rd hour Min-Max(Median) 0-8 (3) 0-8 (4) 0-8 (3) χ2:0.772
Mean±Std. dev. 3.6±2.3 3.9±2.6 3.3±2.4 0.68
6th hour Min-Max (Median) 1-9 (6) 0-9 (5) 0-9 (4) χ2:4.684
Mean±Std. dev. 5.5±2.2 4.6±3.1 3.7±2.5 0.096
8th hour Min-Max(Median) 1-8 (5) 0-8 (5) 0-9 (5) χ2:1.482
Mean±Std. dev. 5.6±1.9 4.6±2.6 5.1±2.7 c0.477
24th hour Min-Max (Median) 1-8 (5) 0-10 (4) 0-9 (2) χ2:6.512
Mean±Std. dev. 5±2.2a 4.4±3a,b 3.1±2.7b 0.039
2nd day Min-Max (Median) 0-8 (5) 0-9 (4) 0-7 (3) χ2:2.185
Mean±Std. dev. 4.2±2.3 4±2.4 3.1±2.5 0.335
3rd day Min-Max (Median) 0-8 (3) 0-7 (3) 0-7 (2) χ2:0.048
Mean±Std. dev. 2.9±2.1 2.9±2.3 2.8±2.5 0.976
5th day Min-Max (Median) 0-7 (2) 0-5 (1) 0-6 (2) χ2:2.411
Mean±Std. dev. 2.1±2 1.3±1.7 1.9±1.8 0.3
Table 3. Evaluation of the VAS scores according to drug groups.
Kruskal Wallis tests were used to compute the p values; different letters indicate intergroup differences
Fig. 1. The distrubition of VAS scores during assessment times among the groups.





Trometamol + 4mg 
Thiocolchicoside
Dexketoprofen 
Trometamol + 8mg 
Thiocolchicoside
p





0-3 (0) 0-4 (0) 0-1 (0) 0-5 (0) 0-7 (0) 0-6 (1) χ2:4.26 χ2:1.401
Mean±Std. 
dev.





0-8 (1) 0-3 (0.5) 0-5 (0) 0-5 (2) 0-5 (1) 0-6 (1) χ2:0.962 χ2:1.276
Mean±Std. 
dev.





1-8 (3) 0-7 (3) 0-8 (4) 1-8 (4) 0-8 (3) 0-6 (3) χ2:0.552 χ2:0.885
Mean±Std. 
dev.





3-9 (7) 1-7 (4.5) 0-9 (6) 0-8 (3) 0-9 (3) 1-5 (4) χ2:2.470 χ2:2.098
Mean±Std. 
dev.





1-8 (6) 4-7 (5) 0-8(5.5) 2-8 (5) 0-9 (5) 1-9 (5.5) χ2:0.904 χ2:1.610
Mean±Std. 
dev.





2-8 (6) 1-6 (5) 0-10 (6) 1-8 (4) 0-9 (3) 0-5 (2) χ2:3.358 χ2:2.898
Mean±Std. 
dev.





1-8 (5) 0-7 (3.5) 0-9 (4) 0-8 (4) 0-7 (5) 0-5 (2.5) χ2:2.399 χ2:1.166
Mean±Std. 
dev.





0-8 (4) 0-5 (1,5) 0-7 (3) 0-7 (4) 0-5 (2) 0-7 (2.5) χ2:1.236 χ2:1.273
Mean±Std. 
dev.





0-7 (2) 0-6 (0,5) 0-4(0.5) 0-5 (1) 0-5 (2) 0-6 (2) χ2:3.573 χ2:0.917
Mean±Std. 
dev.
2.5±2 1.5±2 1.1±1.4 1.6±2.1 1.7±1.8 2.1±1.9 0.168 0.632
Table 4. Evaluation of the VAS scores according to drug groups in female and male patients.
Kruskal Wallis tests were used to compute the p values
maximum level at the 4th hour in the study by Çağıran 
and colleagues, and at 8th hour in the study by Eroglu 
and colleagues (24,28). Consistent with the literature, 
we found that pain was maximum at the 8th hour in all 
three groups in the present study. Pain levels started to 
decrease by 3rd day in dexketoprofen trometamol and 
dexketoprofen trometamol + 4 mg thiocolchicoside 
groups, and by 24th hour in dexketoprofen trometamol 
+ 8 mg thiocolchicoside group. The reason why pain lev-
els started to fall earlier in dexeketoprofen + 8 mg thio-
colchicoside group compared to the other two groups is 
though to be that the effect was more pronounced after 
receiving the second dose.
In their study, Kirmeier and colleagues investigated the 
efficacy of tizanidine, a central acting muscle relaxant, 
in extraction of impacted lower third molar. They ad-
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Fig. 2. The distrubition of VAS scores during assessment times among the groups in female patients.
Fig. 3. The distrubition of VAS scores during assessment times among the groups in male patients.
ministered tizanidine in combination with dexibupro-
fen, which is a NSAID. 4 mg tizanidine was admin-
istered orally at nighttime on the day of surgery and 
postoperative day 1. They found no difference between 
the groups that did or did not receive tizanidine regard-
ing mean VAS scores on postoperative 1st, 3rd and 7th 
days and mouth opening. They observed maximum lev-
el of pain at the postoperative 24th hour (29).
In a study by de Santana Santos and colleagues, the 
analgesic effect of cyclobenzaprine, a centrally acting 
muscle relaxant, which was started 1 day before sur-
gery and continued on the day of surgery and on the 
first postoperative day, was compared with the placebo 
in patients with bilaterally impacted third molar. In ad-
dition to cyclobenzaprine, 8 mg dexamethasone and 
1 g amoxicillin were administered orally 1 hour prior 
to surgery. Postoperatively, patients used 750 mg acet-
aminophen when needed (maximum 4 times a day). No 
difference was observed between the groups regarding 
analgesic efficacy at postoperative 4th, 6th, 12th, 24th 
and 48th hours. The groups did not show difference re-
garding edema and trismums on postoperative 2nd and 
7th days. Maximum pain was observed at postoperative 
4th and 6th hours (30).
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In this study, the analgesic effect of dexketoprofen 
trometamol + 8 mg thiocolchicoside was found to be 
higher than dexketoprofen trometamol at 24th hour. 
Dexketoprofen + 4 mg thiocolchicoside, showed similar 
analgesic effect with dexketoprofen trometamol. The 
analgesic effect of thiocolchicoside increased with in-
creasing dose. The thiocolchicoside used in this study 
is a central acting muscle relaxant. Other centrally act-
ing muscle relaxants used in the studies, cyclobenzap-
rine and tizanidine, do not create additional analgesic 
effect, and this can be explained by the fact that they 
lack anti-inflammatory action (30). In the study by Kir-
meier colleagues tizanidine was started at night before 
the operation, and this may be the reason for the delayed 
analgesic effect, and for the lack of efficacy within the 
24 hours when the pain is most intense. Additionally, 
the time intervals for assessment of pain could also have 
influenced the results. Unlike the other two muscle re-
laxants (cyclobenzaprine and tizanidine), thiocholchi-
coside that is used in this study has anti-inflammatory 
property. It is thought that increased analgesic efficacy 
of thiocholchicoside at inreasing doses may be related 
to the anti-inflammatory mechanism of action (29). 
When we compare drug side effects observed in stud-
ies using dexketoprofen trometamol, the side effects 
were observed in rates of 10.24% in the study by Bagan 
and colleagues, 11.9% in the study by Jackson and col-
leagues, and 0% in the study by Eroglu and colleagues 
(24,26,27). In the study by De Santana Santos and col-
leagues, in which cyclobenzaprine was combined with 
paracetamol, the rate of side effects was reported as 6% 
(30). In the study by Kirmeier and colleagues, which 
was the only study that combined a NSAID (dexibrufen) 
with a muscle relaxant, no drug related side effect was 
mentioned (29). Unlike the other studies in the litera-
ture, drug side effects were observed in 28.17% of the 
patients in the present study. Most commonly observed 
side effects were gastrointestinal system disturbances 
and headache or dizziness. It was expected that thio-
colchicoside groups that received this drug for 5 days 
would have greater rate of side effects, however, simi-
lar drug side effects were observed in all drug groups. 
Drug side effects are thought to be related to dexketo-
profen trometamol, which is the common drug in all 
three groups.
In conclusion, this study was the first study to use the 
combination of dexketoprofen trometamol + thiocol-
chicoside and to evaluate their analgesic effect in the 
extraction of impacted lower third molar. Within the 
limitations of the study, dexketoprofen trometamol + 8 
mg thiocolchicoside was found to be more effective on 
pain than dexketoprofen trometamol alone at 24th hour. 
More studies are needed to better interpret the analgesic 
and anti-inflammatory effects of the thiocolchicoside + 
dexketoprofen trometamol combination.
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